Search results for: Oncology
Filter search results
OHE at ISPOR Europe 2016: Risk-sharing, Differential Pricing, the Cancer Drugs Fund, and Patient Reported Outcomes
26 October 2016
…and Simona Bianchi (ABPI). The Cancer Drugs Fund (CDF) was created in 2010 to pay for oncology indications that were not approved by the National Institute for Health and Care…
OHE is pleased to appoint two Senior Visiting Fellows: Professor David Parkin and Professor Lou Garrison
5 October 2016
…Evidence Generation Risk-Sharing Agreements Between Pharmaceutical Manufacturers and Payers Personalised Medicine and the Value of Molecular Diagnostics Governance models for real-world evidence The Expanding Value Footprint of Oncology Treatments Lou…
The Dynamics of Drug Shortages
9 January 2024
…Oncology, 24, pp.v17–v22. 10.1093/annonc/mdt324. Eversana, 2022. English Pharmacies Making a Loss When Dispensing Strep A Antibiotics, Amid Surge in Infections. Navlin Daily. Available at: https://www.navlindaily.com/article/15115/english-pharmacies-making-a-loss-when-dispensing-strep-a-antibiotics-amid-surge-in-infections [Accessed 7 Jun. 2023]. Francois, C., Gawlik,…
New Report Published: Improving Efficiency and Resource Allocation in Future Cancer Care
26 September 2016
…addition, case study analyses revealed significant possible savings, such as the €7.1 billion that could be saved during the period 2016-2020, through increased generic and biosimilar competition in the oncology…
A Framework for Value-aligned Pricing of Combination Therapies
25 June 2024
…development of combination therapies becoming more common in oncology and beyond, and a lack of agreed-upon pricing models in Europe, the need for innovative pricing strategies is increasingly evident. The…
Paula Lorgelly Joins the OHE Team as Deputy Director
4 December 2015
…areas of health economics: the determinants of health, economic evaluation and outcome measurement. Most recently she has been working in the clinical areas of oncology, including genomic testing; maternal mental…
Newly Published Analysis: Dementia: the R&D Landscape
16 November 2015
…elsewhere*. Key observations from the literature include: R&D costs are higher for neurology and Alzheimer’s disease (AD) (as well as respiratory and oncology) than other therapy areas Higher costs are…
Chittawan Poonsiri
4 September 2024
…University, Thailand. After graduation, she served as a hospital pharmacist, specializing in oncology patient care. Currently, she is a Senior Associate at the Health Intervention and Technology Assessment Program (HITAP)….
Multi-indication Pricing: Pros, Cons and Applicability to the UK
28 October 2015
…patient per indication, and is the necessary data being generated routinely or requiring ad hoc intervention? There is a UK collaboration to pilot, in oncology, the feasibility of MIP in…